共 50 条
- [31] IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cellsJOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)Zhang, YiPark, MisoGhoda, Lucy Y.Zhao, DandanValerio, MelissaNafie, EbtesamGonzalez, AsaulLy, KevinParcutela, BeaChoi, HyeranGong, XuboChen, FangHarada, KaitoChen, ZhenhuaNguyen, Le Xuan TruongPichiorri, FlaviaChen, JianjunSong, JooForman, Stephen J.Amanam, IdoroenyiZhang, BinJin, JieWilliams, John C.Marcucci, Guido
- [32] Potent Antitumor Activity Generated by a Novel Tumor Specific Cytotoxic T CellPLOS ONE, 2013, 8 (06):Wang, ZhengLi, PeiXu, QinhongXu, JunLi, XuqiZhang, XufengMa, QingyongWu, Zheng
- [33] A DUAL TARGETING CD33/CD123 NANOBODY® T-CELL ENGAGER WITH POTENT ANTI-AML ACTIVITY AND A MANAGEABLE SAFETY PROFILEJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1242 - A1242Dullaers, MelissaDeschamps, GeertBonnevaux, HeleneGuerif, StephaneDe Brabandere, VeroniqueAmara, CelineBrige, AnnDejonckheere, ElineVirone-Oddos, AngelaChiron, MarielleRoobrouck, Annelies
- [34] Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinomaPLOS ONE, 2022, 17 (03):Sangsuwannukul, ThanichSupimon, KamonlapatChieochansin, ThaweesakChoomee, KornkanSujjitjoon, JatupornJunking, MutitaYenchitsomanus, Pa-Thai
- [35] LNAplus™ antisense oligonucleotides targeting CD39 and CD73 have potent anti-tumor activity by modulating immunosuppressive tumor microenvironmentCANCER RESEARCH, 2019, 79 (13)Festag, JuliaThelemann, TamaraKashyap, Abhishek S.Klar, RichardKallert, SandraBuchi, MelanieHinterwimmer, LisaSchell, MonikaRaith, StefanieMichel, SvenZippelius, AlfredJaschinski, Frank
- [36] CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+T cells and immunosuppressive myeloid cellsCELL REPORTS MEDICINE, 2023, 4 (08)Zhang, YuhanHu, JunyiJi, KaiJiang, ShengpengDong, YangSun, LinWang, JunHu, GuangyuanChen, DaweiChen, KeTao, Zhen
- [37] A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemiaBLOOD ADVANCES, 2020, 4 (05) : 906 - 919Nair-Gupta, PriyankaDiem, MichaelReeves, DaraWang, WeirongSchulingkamp, RobertSproesser, KatrinMattson, BethanyHeidrich, BradleyMendonca, MarkJoseph, JocelinSendecki, JocelynFoulk, BradChu, GeraldFink, DamienJiao, QunWu, Sheng-JiunPackman, KathrynElsayed, YusriAttar, RicardoGaudet, Francois
- [38] Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid LeukemiaCANCER DISCOVERY, 2020, 10 (10) : 1544 - 1565Aroua, NesrineBoet, EmelineGhisi, MargheritaNicolau-Travers, Marie-LaureSaland, EstelleGwilliam, Ryande Toni, FabienneHosseini, MohsenMouchel, Pierre-LucFarge, ThomasBosc, ClaudieStuani, LucilleSabatier, MarieMazed, FettaLarrue, ClementJarrou, LatifaGandarillas, SarahBardotti, MassimilianoPicard, MurielSyrykh, CharlotteLaurent, CamilleGotanegre, MathildeBonnefoy, NathalieBellvert, FloriantPortais, Jean-CharlesNicot, NathalieAzuaje, FranciscoKaoma, TonyJoffre, CarineTamburini, JeromeRecher, ChristianVergez, FrancoisSarry, Jean-Emmanuel
- [39] Selective inhibition of STAT5 expression in acute myeloid leukemia cells results in potent antitumor activityCANCER RESEARCH, 2009, 69Zhou, TianyuanGuo, ShulingSiwkowski, AndyWitchell, DonnaPandey, SanjayMonia, BrettMacLeod, RobertKim, Youngsoo
- [40] Targeting SIRT1 Activity: a Novel Strategy for Acute Myeloid Leukemia TherapyEUROPEAN JOURNAL OF CANCER, 2012, 48 : 163 - 163Nawrocki, S. T.Kelly, K. R.Espitia, C. M.Bachier, C.Bornmann, W. G.Carew, J. S.